Protein C replacement in severe meningococcemia: Rationale and clinical experience

Clinical Infectious Diseases

Volumn 32, Issue 9, 2001, Pages 1338-1346

  Alberio, Lorenzo ^a   Laämmle, Bernhard ^a   Esmon, Charles T ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ACUTE PHASE PROTEIN; ALPHA 1 ANTITRYPSIN; BINDING PROTEIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9A; BRADYKININ; CYTOKINE; FIBRINOGEN; HEPARIN; KININOGEN; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PLASMINOGEN ACTIVATOR INHIBITOR; PREKALLIKREIN; PROTEIN S; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; THROMBIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; DISEASE SEVERITY; HUMAN; INFLAMMATION; MENINGOCOCCEMIA; MORTALITY; NEISSERIA MENINGITIDIS; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; SIDE EFFECT; SUBSTITUTION THERAPY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; BACTEREMIA; BLOOD COAGULATION; HUMANS; MENINGOCOCCAL INFECTIONS; PROTEIN C;

EID: 0035341175     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/319995     Document Type: Article

References (94)

1. Regulatory mechanisms in hemostasis: Natural anticoagulants
2. Control of coagulation reactions
3. Protein S and C4b-binding protein: Components involved in the regulation of the protein C anticoagulant system
4. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor
5. High affinity binding sites for activated protein C and protein C on cultured human umbilical vein endothelial cells, independent of protein S and distinct from known ligands
6. Structural prediction and analysis of endothelial cell protein C/activated protein C receptor
7. Human protein C receptor is present primarily on endothelium of large blood vessels: Implications for the control of the protein C pathway
8. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex
9. The endothelial cell protein C receptor. Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors
10. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates
11. Inflammation and thrombosis: Mutual regulation by protein C
12. Generation of fibrinolyric activity by infusion of activated protein C into dogs
13. Complement activation during subsequent stages of canine endotoxin shock
14. Complement activation and endotoxin levels in systemic meningococcal disease
15. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin
16. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin
17. Interleukin-1 (IL-1) receptor blockade reduces endotoxin and Borrelia burgdorferi-stimulated IL-8 synthesis in human mononuclear cells
18. Disseminated intravascular coagulation
19. Purpura fulminans in meningococcemia: Association with acquired deficiencies of proteins C and S
20. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans
21. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways
22. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: Related to an unfavourable prognosis
23. The structural biology of expression and function of tissue factor
24. Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells
25. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro
26. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane: Studies in Scott syndrome - An isolated defect in platelet procoagulant activity
27. Platelet procoagulant activity: Physiological significance and mechanisms of exposure
28. Infusion of phospholipid vesicles amplifies the local thrombotic response to TNF and anti-protein C into a consumptive response
29. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis
30. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment
31. Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons
32. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells
33. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture
34. Transcriptional regulation of the thrombomodulin gene
35. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity
36. Regulatory mechanisms for thrombomodulin expression in human umbilical vein endothelial cells in vitro
37. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity: A potential rapid mechanism for modulation of coagulation
38. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: In vivo and in vitro studies
39. Physiologic inhibition of human activated protein C by alpha 1-antitrypsin
40. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation
41. Response of blood leukocytes to thrombin receptor peptides
42. Linkage between inflammation and coagulation: An update on the molecular basis of the crosstalk
43. Thrombin-induced chemotaxis and aggregation of neutrophils
44. Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin
45. Thrombin induces endothelial type II activation in vitro: IL-1 and TNF- alpha-independent IL-8 secretion and E-selectin expression
46. Monocyte chemotaxis: Stimulation by specific exosite region in thrombin
47. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation
48. Inflammatory roles of P-selectin
49. Vascular endothelial cell activation and permeability responses to thrombin
50. Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event
51. Interaction with autologous platelets multiplies interleukin-1 and tumor necrosis factor production in mononuclear cells
52. Factor Xa as an interface between coagulation and inflammation: Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo
53. A model for thrombin protection against endotoxin
54. Endogenous anticoagulation during extracorporeal perfusion: Generation of a heparinlike inhibitor
55. Recovery from endotoxin shock after extracorporeal perfusion without anticoagulation
56. Isolation and characterization of an in vivo thrombin-induced anticoagulant activity
57. Activation of protein C in vivo
58. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon
59. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats
60. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production
61. Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits
62. C4b-binding protein exacerbates the host response to Escherichia coli
63. Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli
64. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage
65. The anticoagulants protein C and protein S display potent antiinflammatory and immunosuppressive effects relevant to transplant biology and therapy
66. Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes
67. Tumor necrosis factor production during human renal allograft rejection is associated with depression of plasma protein C and free protein S levels and decreased intragraft thrombomodulin expression
68. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses
69. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-γ, or phorbol ester
70. A physiologic anti-inflammatory pathway based on thrombomodulin expression and generation of activated protein C by human mononuclear phagocytes
71. Differential effect of tumor necrosis factor-alpha on thrombomodulin gene expression by human monocytoid (THP-1) cells versus endothelial cells
72. Endothelial protein C receptor
73. Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor shedding in vivo
74. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis
75. Neisseria meningitidis
76. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease
77. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency
78. Coagulation activation and tissue necrosis in meningococcal septic shock: Severely reduced protein C levels predict a high mortality
79. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate
80. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency
81. Purpura fulminans in severe congenital protein C deficiency: Monitoring of treatment with protein C concentrate
82. Treatment of patients with disseminated intravascular coagulation by protein C
83. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: Treatment with protein C concentrate
84. Treatment of purpura fulminans in meningococcemia with protein C concentrate
85. Protein C in the treatment of coagulopathy in meningococcal disease
86. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans
87. Protein C replacement therapy for meningococcal induced purpura fulminans
88. Infectious purpura fulminans: Diagnosis and treatment
89. Protein-C concentrate for meningococcal purpura fulminans
90. Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans
91. Trends in mortality in children hospitalized with meningococcal infections, 1957 to 1987
92. Adult overwhelming meningococcal purpura: A study of 35 cases, 1977-1989
93. Update on meningococcal disease with emphasis on pathogenesis and clinical management
94. Pathophysiology, treatment and outcome of meningococcemia: A review and recent experience